Drug Trial Radar · NCT01728155
European Low and Intermediate Risk Neuroblastoma Protocol
Last checked: Nov 20, 2026Latest source record: Sep 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
685
Actual
Start
Jan 1, 2011
Primary completion
Dec 31, 2022
Sponsor
- Lead sponsor
- Instituto de Investigacion Sanitaria La FeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 16, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 90 days, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The European study, LINES 2009 (Low and Intermediate Risk Neuroblastoma European Study), groups together in a single protocol the treatment of all patients with "non high risk" neuroblastoma (NB), with stratification into two groups: low risk and intermediate risk. These two separate cohorts are included in one single protocol to enable patient data from these two groups to be entered into a common database, as the current prognostic classifications determining treatment may evolve further with subsequent more detailed molecular analysis of the tumours. 1\. LOW RISK STUDY The Low Risk Study is proposed in order to: * minimise the amount of treatment (chemotherapy and surgery) for all appropriate low risk patients, who in previous studies have been shown to have an excellent long-term outcome (as in the SIOPEN 99.1-2 infant neuroblastoma studies where the overall survival was greater than 97%(H. Rubie, JCO). * improve the EFS and maintain the OS (overall survival) in L2 and Ms patients with a SCA(Segmental Cromosomal Aberration) genomic profile tumour (presence of any segmental chromosomal change (SCA)) by electively treating these patients with chemotherapy despite the absence of symptoms. 2\) INTERMEDIATE RISK STUDY The Intermediate Risk Study is proposed in order to: * reduce the amount of chemotherapy for differentiating histology INRG (International Neuroblastoma Risk Group) stage L2 NB and ganglioneuroblastoma nodular patients who in previous SIOPEN study have been shown to have an excellent long-term outcome; * increase the amount of treatment (radiotherapy and 13-cis-RA (13-cis-Retinoic Acid) for poorly differentiated or undifferentiated histology INRG stage L2 NB or ganglioneuroblastoma nodular patients in order to improve the EFS registered in the previous SIOPEN study; * improve the EFS (Event Free Survival) of MYCN (V-Myc myelocytomatosis viral related oncogene, NB derived ,avian )amplified INSS (International NB Staging System) stage 1 NB patients with the introduction of adjuvant treatment; * maintain the very good results obtained in previous SIOPEN study for INRG stage M infants with a moderate treatment. NEONATAL SUPRARENAL MASSES The incidence of suprarenal tumours/masses has increased in the last decade due to the expanded use of prenatal ultrasonography in routine obstetric care and in the neonatal and early infancy care. The differential diagnosis of these masses ranges from benign (adrenal haemorrhage) to malignant processes (neuroblastoma, adrenal carcinoma). Knowledge on perinatal suprarenal masses, although based on a relatively large literature, is scattered amongst studies on very few cases with no methodical approach and often short follow up. Therefore, the optimal management of these masses has not been clearly defined. Neuroblastoma at this age is an intriguing entity with a very good prognosis in most cases. The SIOPEN Group, based on their results in the first multicenter European Trial for infants with neuroblastoma (INES) and the world-wide experience provided in the literature, is launching this European surveillance study (Multi-centre, non-blinded, one armed prospective trial) for these masses. Treatment: Observation
Conditions
- LOW AND INTERMEDIATE PAEDIATRIC NEUROBLASTOMA AND NEONATAL SUPRARENAL MASSES
Interventions
chemotherapyDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary aim for Low Risk NeuroblastomaTime frame: 2 years
- Primary aim for Intermediate Risk NeuroblastomaTime frame: 2 years
- Primary Aim for Neonatal Suprarenal MassesTime frame: 3 year
Locations
98 sites in 10 countries. Site status is shown where the registry gives one.
Monash Children's Hospital
Clayton, Australia
Perth Children's Hospital
Nedlands, Australia
Sydney Children's Hospital
Sydney, Australia
PHO Med Uni Graz
Graz, Austria
Department Kinder- und Jugendheilkunde
Innsbruck, Austria
Landes-Frauen- und Kinderklinik Linz
Linz, Austria
St. Anna Kinderspital
Vienna, Austria
Univ Klinik für Kinder- und Jugendheilkunde
Vienna, Austria
Hôpital Universitaire d'Anvers (UZA- Universitair Ziekenhuis Antwerpen)
Antwerp, Belgium
Hôpital Universitaire des Enfants Reine Fabiola (HUDERF)
Brussels, Belgium
UCL Clíniques Universitaires Saint - Luc
Brussels, Belgium
Universitair Ziekenhuis Brussel
Brussels, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Universitair Ziekenhuis Leuven
Leuven, Belgium
CHC- Clinique de l'Espérance à Liège
Liège, Belgium
CHR de la Citadelle
Liège, Belgium
Aarhus University Hospital
Aarhus, Denmark
National State Hospital (Department of Pediatrics)
Copenhagen, Denmark
University Hospital of Odense (H.C. Andersen Children´s Hospital)
Odense, Denmark
Soroka Medical Center
Beersheba, Israel
Rambam Health Care Campus
Haifa, Israel
Schneider Children's Medical Center
Petah Tikva, Israel
Ichilov Hospital Sourasky Medical Center
Tel Aviv, Israel
Ospedale Pediatrico G. Salesi di Ancona (Centro Regionale Oncoematologia Pediatrica)
Ancona, Italy
Azienda Ospedaliera - Universitaria Ospedale Policlinico Consorziale
Bari, Italy
Azienda Ospedaliera Ospedali Riuniti di Bergamo
Bergamo, Italy
Azienda Ospedaliero- Universitaria di Bologna- Policlinico S. Orsola - Malpighi
Bologna, Italy
Azienda Ospedaliera Spedali Civili di Brescia
Brescia, Italy
Ospedale Microcitemico
Cagliari, Italy
Oncology Policlinico- Department of Hematology
Catania, Italy
Azienda Ospedaliero-Universitaria di Ferrara- Oncoematologia Pediatrica
Ferrara, Italy
Azienda Ospedaliero-Universitaria Ospedale Pediatrico Meyer
Florence, Italy
Oncology Gaslini Children's Hospital of Genova- Department of Hematology
Genova, Italy
Istituto Nazionale dei Tumori di Milano- Onco-ematologia Pediatrica
Milan, Italy
Azienda Ospedaliero-Universitaria Policlinico di Modena- Onco-ematologia Pediatrica
Modena, Italy
Azienda Ospedaliera Pediatrica Santobono Pausilipon
Naples, Italy
Sec. Università degli studi di Napoli - Policlinico
Naples, Italy
Azienda Ospedaliera-Universitaria di Padova- Clínica di Onco-ematologia Pediatrica
Padova, Italy
Ospedale dei Bambini G. Di Cristina
Palermo, Italy
Azienda Ospedaliero - Universitaria di Parma- Oncoematologia Pediatrica
Parma, Italy
Showing 40 of 98 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.